KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Change in Receivables (2017 - 2025)

Historic Change in Receivables for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $1.0 million.

  • Bionano Genomics' Change in Receivables rose 20944.8% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$359000.0, marking a year-over-year increase of 8930.27%. This contributed to the annual value of -$4.1 million for FY2024, which is 28027.0% down from last year.
  • Latest data reveals that Bionano Genomics reported Change in Receivables of $1.0 million as of Q3 2025, which was up 20944.8% from $141000.0 recorded in Q2 2025.
  • Bionano Genomics' 5-year Change in Receivables high stood at $1.2 million for Q3 2022, and its period low was -$2.1 million during Q2 2024.
  • For the 5-year period, Bionano Genomics' Change in Receivables averaged around $35526.3, with its median value being $157000.0 (2021).
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 61146.5% in 2022, then tumbled by 34759.62% in 2024.
  • Quarter analysis of 5 years shows Bionano Genomics' Change in Receivables stood at $157000.0 in 2021, then soared by 611.46% to $1.1 million in 2022, then crashed by 41.81% to $650000.0 in 2023, then plummeted by 120.46% to -$133000.0 in 2024, then soared by 875.19% to $1.0 million in 2025.
  • Its Change in Receivables was $1.0 million in Q3 2025, compared to $141000.0 in Q2 2025 and -$1.4 million in Q1 2025.